Holen Sie sich die Stockscreener-App
12.53
11.58%
1.30
Handel nachbörslich:
12.40
-0.13
-1.04%
Schlusskurs vom Vortag:
$11.23
Offen:
$11.3
24-Stunden-Volumen:
719.23K
Relative Volume:
2.56
Marktkapitalisierung:
$772.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.79M
KGV:
-10.28
EPS:
-1.2185
Netto-Cashflow:
$-54.55M
1W Leistung:
+20.83%
1M Leistung:
+24.68%
6M Leistung:
+97.32%
1J Leistung:
+268.53%
1-Tages-Spanne:
$11.27
$12.62
1-Wochen-Bereich:
$10.55
$12.62
52-Wochen-Spanne:
$2.60
$12.62
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
12.53 | 692.58M | 0 | -69.79M | -54.55M | -1.2185 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Panic Selling: What is the long term forecast for Design Therapeutics Inc stockMarket Risk Report & Community Verified Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
DSGN.O PE Ratio & Valuation, Is DSGN.O Overvalued - intellectia.ai
DSGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oppenheimer initiates coverage of Design Therapeutics (DSGN) with outperform recommendation - MSN
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighHere's What Happened - MarketBeat
Director David Shapiro granted 67,500 DSGN stock options (DSGN) - Stock Titan
Design Therapeutics (DSGN) director David Shapiro submits Form 3 - Stock Titan
Design Therapeutics, Inc. Appoints David Shapiro, M.D. as Class III Director and as Nominating and Corporate Governance Committee Member, Effective March 31, 2026 - marketscreener.com
David Shapiro joins Design Therapeutics (DSGN) board with equity awards - Stock Titan
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Value Recap: Can Design Therapeutics Inc expand its profit marginsEarnings Miss & Capital Efficient Trading Techniques - baoquankhu1.vn
Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company - businesswire.com
DSGN.O Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - msn.com
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - barchart.com
Fed Meeting: Will Design Therapeutics Inc benefit from current market trendsDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
DSGN Earnings History & Surprises | EPS & Revenue Results | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
DSGN Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026 - Business Wire
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics - The Manila Times
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates Design Therapeutics stock with buy on drug potential - investing.com
Jefferies initiates Design Therapeutics stock with buy on drug potential By Investing.com - Investing.com Australia
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan
Piper Sandler reiterates Overweight on Design Therapeutics stock By Investing.com - Investing.com South Africa
RBC Capital raises Design Therapeutics stock price target on programs By Investing.com - Investing.com Australia
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - The Manila Times
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):